Table of Contents Author Guidelines Submit a Manuscript
International Journal of Cell Biology
Volume 2017 (2017), Article ID 1873834, 10 pages
https://doi.org/10.1155/2017/1873834
Research Article

Thrombopoietin Secretion by Human Ovarian Cancer Cells

1Lariboisière Hospital, University of Sorbonne Paris Cité-Paris Diderot 7, INSERM U965, 75010 Paris, France
2Faculty of Pharmacy, University of Monastir, 5000 Monastir, Tunisia
3Diagnostica Stago, 92230 Gennevilliers, France

Correspondence should be addressed to Massoud Mirshahi

Received 2 November 2016; Revised 23 January 2017; Accepted 14 February 2017; Published 30 March 2017

Academic Editor: Anton M. Jetten

Copyright © 2017 Samaher Besbes et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Trousseau, Clinique Médicale de l'Hôtel-Dieu de Paris, Baillière, 1865.
  2. H. R. Buller, F. F. Van Doormaal, G. L. Van Sluis, and P. W. Kamphuisen, “Cancer and thrombosis: from molecular mechanisms to clinical presentations,” Journal of Thrombosis and Haemostasis, vol. 5, no. 1, pp. 246–254, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Levin and C. L. Conley, “Thrombocytosis associated with malignant disease,” Archives of Internal Medicine, vol. 114, no. 4, pp. 497–500, 1964. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Z. Wojtukiewicz, E. Sierko, and W. Kisiel, “The role of hemostatic system inhibitors in malignancy,” in Seminars in Thrombosis and Hemostasis, pp. 621–642, Stratton Intercontinental Medical Book Corporation, New York, NY, USA, 2007. View at Google Scholar
  5. R. L. Bick, “Coagulation abnormalities in malignancy: a review,” Seminars in Thrombosis and Hemostasis, vol. 18, no. 4, pp. 353–372, 1992. View at Publisher · View at Google Scholar · View at Scopus
  6. A. A. Khorana, C. W. Francis, E. Culakova, and G. H. Lyman, “Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study,” Cancer, vol. 104, no. 12, pp. 2822–2829, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. N. M. Bambace and C. E. Holmes, “The platelet contribution to cancer progression,” Journal of Thrombosis and Haemostasis, vol. 9, no. 2, pp. 237–249, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Boucharaba, C.-M. Serre, S. Grès et al., “Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer,” Journal of Clinical Investigation, vol. 114, no. 12, pp. 1714–1725, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. F. J. De Sauvage, P. E. Hass, S. D. Spencer et al., “Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand,” Nature, vol. 369, no. 6481, pp. 533–538, 1994. View at Publisher · View at Google Scholar · View at Scopus
  10. D. V. Jones Jr., M. Ashby, S. Vadhan-Raj et al., “Recombinant human thrombopoietin clinical development,” Stem Cells, vol. 16, pp. 199–206, 1998. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Sungaran, B. Markovic, and B. H. Chong, “Localization and regulation of thrombopoietin mRNA expression in human kidney, liver, bone marrow, and spleen using in situ hybridization,” Blood, vol. 89, no. 1, pp. 101–107, 1997. View at Google Scholar · View at Scopus
  12. Y. Sohma, H. Akahori, N. Seki et al., “Molecular cloning and chromosomal localization of the human thrombopoietin gene,” FEBS Letters, vol. 353, no. 1, pp. 57–61, 1994. View at Publisher · View at Google Scholar
  13. D. C. Foster, C. A. Sprecher, F. J. Grant et al., “Human thrombopoietin: gene structure, cDNA sequence, expression, and chromosomal localization,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 26, pp. 13023–13027, 1994. View at Publisher · View at Google Scholar · View at Scopus
  14. A. L. Gurney, W.-J. Kuang, M.-H. Xie, B. E. Malloy, D. L. Eaton, and F. J. De Sauvage, “Genomic structure, chromosomal localization, and conserved alternative splice forms of thrombopoietin,” Blood, vol. 85, no. 4, pp. 981–988, 1995. View at Google Scholar · View at Scopus
  15. R. Marcucci and M. Romano, “Thrombopoietin and its splicing variants: structure and functions in thrombopoiesis and beyond,” Biochimica et Biophysica Acta—Molecular Basis of Disease, vol. 1782, no. 7-8, pp. 427–432, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. A. V. Sirotkin, P. Sanislo, H.-J. Schaeffer et al., “Thrombopoietin regulates proliferation, apoptosis, secretory activity and intracellular messengers in porcine ovarian follicular cells: involvement of protein kinase A,” Journal of Endocrinology, vol. 183, no. 3, pp. 595–604, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Sasaki, T. Takahashi, H. Miyazaki et al., “Production of thrombopoietin by human carcinomas and its novel isoforms,” Blood, vol. 94, no. 6, pp. 1952–1960, 1999. View at Google Scholar · View at Scopus
  18. M. Furuhashi, Y. Miyabe, and H. Oda, “A case of thrombopoietin-producing ovarian carcinoma confirmed by immunohistochemistry,” Gynecologic Oncology, vol. 74, no. 2, pp. 278–281, 1999. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Tsukishiro, N. Suzumori, H. Nishikawa, A. Arakawa, and K. Suzumori, “Preoperative serum thrombopoietin levels are higher in patients with ovarian cancer than with benign cysts,” European Journal of Obstetrics Gynecology and Reproductive Biology, vol. 140, no. 1, pp. 67–70, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Kaser, G. Brandacher, W. Steurer et al., “Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis,” Blood, vol. 98, no. 9, pp. 2720–2725, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. L. Columbyova, M. Loda, and D. T. Scadden, “Thrombopoietin receptor expression in human cancer cell lines and primary tissues,” Cancer Research, vol. 55, no. 16, pp. 3509–3512, 1995. View at Google Scholar · View at Scopus
  22. D. Azzazene, H. A. Thawadi, H. A. Farsi et al., “Plasma endothelial protein C receptor influences innate immune response in ovarian cancer by decreasing the population of natural killer and TH17 helper cells,” International Journal of Oncology, vol. 43, no. 4, pp. 1011–1018, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Marty, C. Saint-Martin, C. Pecquet et al., “Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors,” Blood, vol. 123, no. 9, pp. 1372–1383, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. T. D. Schmittgen and K. J. Livak, “Analyzing real-time PCR data by the comparative CT method,” Nature Protocols, vol. 3, no. 6, pp. 1101–1108, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Tada, O. Shiho, K.-I. Kuroshima, M. Koyama, and K. Tsukamoto, “An improved colorimetric assay for interleukin 2,” Journal of Immunological Methods, vol. 93, no. 2, pp. 157–165, 1986. View at Publisher · View at Google Scholar · View at Scopus
  26. Z. Estrov, M. Talpaz, G. Mavligit et al., “Elevated plasma thrombopoietic activity in patients with metastatic cancer-related thrombocytosis,” The American Journal of Medicine, vol. 98, no. 6, pp. 551–558, 1995. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Suzuki, T. Takahashi, K. Nakamura et al., “Thrombocytosis in patients with tumors producing colony-stimulating factor,” Blood, vol. 80, no. 8, pp. 2052–2059, 1992. View at Google Scholar · View at Scopus
  28. R. L. Stone, A. M. Nick, I. A. McNeish et al., “Paraneoplastic thrombocytosis in ovarian cancer,” New England Journal of Medicine, vol. 366, no. 19, pp. 610–618, 2012. View at Publisher · View at Google Scholar
  29. M. Sarkar, S. Schilffarth, D. Schams, H. H. D. Meyer, and B. Berisha, “The expression of thrombopoietin and its receptor during different physiological stages in the bovine ovary,” Reproduction in Domestic Animals, vol. 46, no. 5, pp. 757–762, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. P. J. Fielder, A. L. Gurney, E. Stefanich et al., “Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets,” Blood, vol. 87, no. 6, pp. 2154–2161, 1996. View at Google Scholar · View at Scopus
  31. H. Althawadi, H. Alfarsi, S. Besbes et al., “Activated protein C upregulates ovarian cancer cell migration and promotes unclottability of the cancer cell microenvironment,” Oncology Reports, vol. 34, no. 2, pp. 603–609, 2015. View at Publisher · View at Google Scholar · View at Scopus
  32. C. R. Hutchinson, L. Shu-Wen, A. G. McInnes, and J. A. Walter, “Comparative biochemistry of fatty acid and macrolide antibiotic (brefeldin a). Formation in penicillium brefeldianum,” Tetrahedron, vol. 39, no. 21, pp. 3507–3513, 1983. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Kiontke, L. Langemeyer, A. Kuhlee et al., “Architecture and mechanism of the late endosomal Rab7-like Ypt7 guanine nucleotide exchange factor complex Mon1–Ccz1,” Nature Communications, vol. 8, Article ID 14034, 2017. View at Publisher · View at Google Scholar